Veronique Lecault - 30 Nov 2021 Form 4/A - Amendment Insider Report for AbCellera Biologics Inc. (ABCL)

Role
Chief Operating Officer, Director
Signature
/s/ Tryn Stimart, attorney-in-fact
Issuer symbol
ABCL
Transactions as of
30 Nov 2021
Net transactions value
+$15,833
Form type
4/A - Amendment
Filing time
03 Dec 2021, 16:47:51 UTC
Date Of Original Report
02 Dec 2021
Previous filing
16 Jun 2021
Next filing
09 Dec 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ABCL Common Shares Options Exercise $15,833 +83,333 +6.2% $0.1900* 1,422,666 30 Nov 2021 Direct F1
holding ABCL Common Shares 7,155,008 30 Nov 2021 See Footnote F2
holding ABCL Common Shares 273,630 30 Nov 2021 See Footnote F3
holding ABCL Common Shares 61,580 30 Nov 2021 By spouse

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ABCL Share Option (right to buy) Options Exercise $0 +83,333 +3.1% $0.000000 2,774,134 30 Nov 2021 Common Shares 83,333 $0.1900 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The original price was listed as $14.96 which is an administrative error. The correct price is $0.19.
F2 These shares are held by Pacific Swell Capital Corp ("Pacific Swell"). The Reporting Person is a director of Pacific Swell and shares voting and dispositive power with respect to the shares held by Pacific Swell. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of her indirect pecuniary interest therein.
F3 These shares are held by Slomo Family Trust. The Reporting Person is a co-trustee of the Slomo Family Trust. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of her indirect pecuniary interest therein.
F4 The shares subject to such option vest and become exercisable annually in substantially equal installments over a six-year period, with the first tranche vested on November 8, 2017, subject to the Reporting Person's continuous service to the Issuer on each such date.